Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Japanese Drugmakers Sign With U.S. Firms
by Jean-François Tremblay
January 4, 2010
| A version of this story appeared in
Volume 88, Issue 1
Japan’s Astellas Pharma and Ambit Biosciences will codevelop AC220, Ambit’s treatment for acute myeloid leukemia, a fatal form of blood cancer. Astellas will make an initial cash payment of $40 million to San Diego-based Ambit and pay as much as $350 million to the firm if the product gains approval. AC220 is a kinase inhibitor that recently entered Phase II clinical trials. Separately, Japan’s Eisai will pay $255 million to acquire New Jersey-based AkaRx, which has developed AKR-501, an agonist for thrombopoietin receptors, which stimulate platelet production.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter